Prolongation of allogeneic transplanted skin grafts and induction of tolerance by leflunomide, a new immunosuppressive isoxazol derivative.
Schorlemmer
H U
HU
Research Laboratories of Behringwerke AG, Marburg/Lahn, Germany.
Seiler
F R
FR
Bartlett
R R
RR
D000818:Animals; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000276:immunology; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology*; D007108:Immune Tolerance; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007555:Isoxazoles / Q000627:therapeutic use*; D000077339:Leflunomide; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology; D051381:Rats; D011914:Rats, Inbred BN; D011916:Rats, Inbred F344; D011919:Rats, Inbred Strains; D016038:Skin Transplantation / Q000276:immunology*; D013154:Spleen / Q000187:drug effects / Q000276:immunology; D013997:Time Factors; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents; D007555:Isoxazoles; D016572:Cyclosporine; D000077339:Leflunomide